Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 111.37B -2.8% |
| Revenue (ttm) | 12.22B +10.1% |
| Net Income | 4.34B |
| EPS | 16.86 |
| Shares Out | 253.81M |
| PE Ratio | 25.84 |
| Forward PE | 22.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 329,702 |
| Open | 437.51 |
| Previous Close | 435.71 |
| Day's Range | 435.21 - 440.88 |
| 52-Week Range | 362.50 - 507.92 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 548.69 (+25.05%) |
| Earnings Date | May 4, 2026 |
About VRTX
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 33 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $548.69, which is an increase of 25.05% from the latest price.
News
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Vertex Pharmaceuticals presents new data on Casgevy at EHA
Vertex Pharmaceuticals (VRTX) announced data demonstrating the clinical benefits of Casgevy in people ages 5 years and older living with severe sickle cell disease or transfusion-dependent beta thalas...
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and o...
Vertex Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing its leadership in cystic fibrosis, pain, and kidney autoimmune therapies, with major pipeline assets in late-stage development and a focus on innovation-driven growth. ALYFTREK and POVI are positioned as best-in-class in their respective markets, while business development and capital allocation remain centered on R&D and select acquisitions.
Vertex Pharmaceuticals presents data on ALYFTREK in children with CF
Vertex Pharmaceuticals (VRTX) announced data demonstrating the potentially transformative impact of treating cystic fibrosis with ALYFTREK in children ages 2 to 5, as well as data from 96-week interim...
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (v...
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalrama...
Vertex announces U.S. FDA accepted BLA submission for povetacicept
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration, FDA, has accepted its Biologics License Application, BLA, submission for povetacicept, an investigational engineered fusi...
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission ...
Vertex Pharmaceuticals Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Expanded from CF to pain, hematology, and renal franchises, with strong launches and pipeline progress. ALYFTREK is now the CF standard, JOURNAVX is rapidly growing in pain, and the renal franchise is poised for major impact with multiple late-stage programs.
Vertex Pharmaceuticals assumed with a Buy at Truist
Truist assumed coverage of Vertex Pharmaceuticals (VRTX) with a Buy rating and price target of $542, up from $525. The firm believes Vertex’s emerging kidney franchise can grow into blockbuster…
Vertex announces Health Canada acceptance of NDS for suzetrigine
Vertex Pharmaceuticals (VRTX) announced that Health Canada has accepted for review a New Drug Submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Suzetrigine is a ...
Vertex Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Growth in CF is driven by innovation, younger patient access, and global expansion, with ALYFTREK and TRIKAFTA label expansions fueling future gains. JOURNAVX is set for significant revenue growth as coverage expands. Povi shows strong efficacy in IgAN and is advancing in multiple indications.
Vertex to Participate in Upcoming May Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial...
Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $607 and keeps an Overweight rating on the shares.
Vertex Pharmaceuticals announces Casgevy reimbursement agreement
Vertex Pharmaceuticals (VRTX) Incorporated announced that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY. This agreement secures sust...
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therap...
Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $616 from $612 and keeps an Overweight rating on the shares. Q1 results were “uneventful” and FY26 guidance…
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $543 from $541 and keeps an Outperform rating on the shares. Shares have been weak…
Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
Canaccord lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $436 from $437 and keeps a Hold rating on the shares. The firm said they reported a slight top-line…
Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein
Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $572 from $577 and keeps an Outperform rating on the shares. The firm notes revenue was in line while…
Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals
The company states: “Today, Vertex (VRTX) announced that it has decided to discontinue the Phase 1/2 study of the investigational inhaled CFTR mRNA candidate for cystic fibrosis, VX-522. Despite exten...
Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 8% year-over-year to $2.99B, with strong growth in CF and new products like ALYFTREK, CASGEVY, and JOURNAVX. Robust R&D and commercial execution support 2026 guidance of $12.95–$13.1B revenue and over $500M from non-CF products.
Vertex Pharmaceuticals Earnings release: Q1 2026
Vertex Pharmaceuticals released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Vertex Pharmaceuticals Slides: Q1 2026
Vertex Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.